# Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)

> **NCT01020487** · PHASE3 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 47 (actual)

## Conditions studied

- Chronic Kidney Disease Stage 3 and 4

## Interventions

- **DRUG:** Paricalcitol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01020487
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2014-05
- **Final completion:** 2014-12
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2018-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01020487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01020487, "Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01020487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*